AgomAb Therapeutics NV AGMB
- Market cap
- $521.1M
- P/E
- —
Follow AGMB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 62 | 62 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (50) | (71) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (50) | (71) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.00) | (162.00) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.03) | (108.19) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.03) | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.06) | (108.19) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 8.14 | 273.71 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 25 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (51) | (59) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (1) | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (51) | (59) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 178 | 116 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (184) | (131) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 204 | 148 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (44.15%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (167.73%) | (240.67%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (49.87%) |
ROE
|
|||
AgomAb Therapeutics NV (AGMB) Latest News
14 Sep
Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and outlined the Phase 2 INSPIRIA study design. Positive Phase 1 data for AGMB-447 advances the company's lead candidate toward Phase 2 trials in a key indication.
6 Aug
Agomab Therapeutics NV reported half-year 2026 financial results and confirmed its 2026 outlook. Half-year results release with confirmed outlook delivers standard performance data likely to produce moderate short-term market reaction.
23 Jun
AgomAb Therapeutics disclosed the NOV-ERA Phase 2b study design for Ontunisertib in fibrostenosing Crohn's disease. Phase 2b study design disclosure signals ongoing pipeline development for Ontunisertib in Crohn's disease.
Agomab announces the design of the NOV-ERA Phase 2b study with ontunisertib in fibrostenosing Crohn’s disease. Phase 2b study design announcement marks continued clinical development of ontunisertib for Crohn’s disease.
12 Apr
AgomAb Therapeutics NV (AGMB) wins U.S. patent for AGMB-447. U.S. patent win for AGMB-447 bolsters AgomAb's intellectual property position and supports product development trajectory.
26 Mar
Agomab Therapeutics NV receives U.S. patent for AGMB-447, its inhaled lung-restricted small molecule ALK5 inhibitor in development for idiopathic pulmonary fibrosis. Patent grant strengthens IP protection for key pipeline asset AGMB-447.
9 Feb
Agomab Therapeutics NV closed its initial public offering. IPO closing delivers major capital infusion and public listing status that can reshape Agomab's funding runway and market visibility.
7 Feb
AgomAb Therapeutics NV priced its IPO at $16 per share, with indications to open trading at $15.50. IPO pricing sets AgomAb Therapeutics NV's initial market valuation and trading trajectory.
5 Feb
Agomab Therapeutics NV priced its initial public offering. IPO pricing marks major capital raise and public listing that shifts company trajectory and investor access.